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Bioisosterism and scaffold hopping are two widely used approaches in medicinal chemistry for the
purpose of lead optimization. The study highlights the physicochemical properties of the 4-hydroxy-1,2,3-
triazole scaffold, a less investigated heterocyclic system. Synthetic strategies to obtain different
N-substituted 4-hydroxy-1,2,3-triazole isomers are presented, and their role as possible isosteres of the
carboxylic acid is discussed. The aim is to use this system to modulate the acidic moieties present in lead
compounds and, at the same time, to regiodirect substituents in set directions, through targeted substitu-
tion on the three nitrogen atoms of the triazole ring. Through this approach, compounds having enhanced
binding affinity, will be sought. Two examples of bioisosteric applications of this moiety are presented. In
the first example, a classical bioisosteric approach mimicking the distal (S)-glutamic acid carboxyl group
using the 4-hydroxy-1,2,3-triazole moiety is applied, to obtain two promising glutamate analogs. In the
second example, a scaffold hopping approach is applied, replacing the phenolic moiety present in MDG-1-
33A, a potent inhibitor of Onchocerca volvulus chitinase, with the 4-hydroxy-1,2,3-triazole scaffold. The
4-hydroxy-1,2,3-triazole system appears to be useful and versatile in drug design.Introduction
Bioisosteric replacement and scaffold hopping are two tech-
niques widely used in drug design to enhance potency, selec-
tivity, and other properties of a lead compound, and to find
new chemical entities with improved features. These tech-
niques may be defined as replacing part of a bioactive mole-
cule with a substructure that is similar in size and that
exhibits similar properties.1 Bioisosterism is an extension of
the concept of isosterism in which two functional groups,known as isosteres, that present similar physicochemical
properties, are related. When isosteres also possess a com-
mon biological profile, they are known as bioisosteres.2
Whereas chemistry dictates the isosteric similarity of groups,
only the biological target can determine their bioisosteric sim-
ilarity. Scaffold hopping is a subset of the bioisosteric replace-
ment process in which the core structure of a small molecule
is replaced. The core may be of direct functional importance
in interacting with the biological target, or it may provide the
necessary scaffold that allows substitution with functional
groups in the appropriate geometric configuration.1 For the
appropriate application of these powerful strategies to drug
design, continuous efforts must be made to develop innova-
tive isosteres that meet specific target requirements. An appli-
cation of bioisosteric substitution as a tool for generating new
antidiabetic lead structures using a family of acidic hydroxy-
azoles was made in 1995 by a team at Wyeth.3 In that paper,
the structure–activity relationship studies determined that the
3-hydroxypirazoles were the most promising new class of
potential antidiabetic agent while the 4-hydroxy-1,2,3-triazole
ring system was not effective. Although, it must be empha-
sized that the study was in vivo and some unknownn., 2015, 6, 1285–1292 | 1285
Fig. 1 General structure of the hydroxytriazole system (A). The system may be used both to (bio)isosterically modulate a carboxylic acid (left),
mainly thanks to the comparatively low pKa value of the hydroxyl group, and to substitute a generic hydroxylated (hetero)aromatic ring (right),
exploiting a scaffold hopping approach.
Fig. 2 Hydroxytriazole system (structure A) and its related hydroxytriazole isomers 1, 2 and 3 together with the benzyl protected forms (general
structure B), and related triazole isomers 4, 5 and 6. Substitutions on the nitrogen atoms are arbitrarily named NĲa), NĲb) and NĲc) for easy
reference.
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View Article Onlinemechanism could interfere with the activity of the studied
compounds. To our knowledge, no other similar application
was subsequently reported on the 4-hydroxy-1,2,3-triazole
system.
This study focuses on the bioisosteric application of the
pentatomic 4-hydroxy-1,2,3-triazole system (hereafter the
hydroxytriazole system, structure A, Fig. 1). The attractive fea-
ture of this system is the possibility it offers to regiodirect
substituents in set directions, by substituting the three nitro-
gen atoms of the triazole ring; this is absent in other
pentatomic heterocyclics (i.e. furazan and thiadiazole). More-
over, the carbon substituent offers the potential to modulate
the pKa of the hydroxyl moiety. This approach might be used
to explore additional binding areas during bioisosteric appli-
cations. Because of its versatility, this system can also be
employed in scaffold hopping, for example it is well suited to
replace a generic hydroxylated aromatic ring (Fig. 1).
This article presents and rationalizes the synthetic strategy
to obtain different N-regio-substituted 4-hydroxy-1,2,3-
triazoles. Structural characterization and physicochemical
properties (pKa and C log P) of some N-substituted isomeric
hydroxytriazoles are also presented. This preparatory study1286 | Med. Chem. Commun., 2015, 6, 1285–1292lays the foundation for future exploitation of hydroxytriazoles
as bioisosteres of acidic functions. We also present two suc-
cessful bioisosteric applications using this moiety. The first
is an example of a classical bioisosteric application, in which
the hydroxytriazole system was successfully used to replace
the distal carboxyl group of (S)-glutamic acid (Glu), the excit-
atory neurotransmitter responsible for major neurodegenera-
tive diseases.4 The second example is of scaffold hopping, in
which the hydroxytriazole system was used to replace the
phenol ring present in MDG-1-33A, a potent and specific
Onchocerca volvulus chitinase (OvCHT1) inhibitor.5 OvCHT1
is hypothesized to play a key role in the life cycle of the worm
parasite responsible for Onchocerciasis, a neglected tropical
disease claimed to be the world's second leading infectious
cause of blindness.Result and discussion
Chemistry
A straightforward and robust chemical strategy to obtain a
series of hydroxytriazole isomers (type A, Fig. 2) is presented.This journal is © The Royal Society of Chemistry 2015
Scheme 1 Synthesis of differently substituted hydroxytriazoles 1, 2 and 3 and their protected forms 4, 5 and 6; (a) diethyl malonate, EtO−Na+,
EtOH, reflux; (b) BnBr, K2CO3, DMF, rt; (c) CAN, CH3CN/H2O Ĳ9/1), rt; (d) R–X, K2CO3, CH3CN, rt; (e) H2/Pd, THF, rt; (f) MeNH2; (g) 0.5 N HCl.
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View Article OnlineThe isomers bearing different substituents on the three nitro-
gen atoms are shown as formulas 1, 2 and 3 (Fig. 2).
The carboxylate substituent offers additional opportunities
for synthetic applications, as it can easily be transformed into
other functional groups to link the triazole scaffold to addi-
tional molecule portions. The general synthetic scheme to
obtain hydroxytriazoles 1, 2 and 3 is shown in Scheme 1.
4-Methoxybenzylazide 7 first underwent regioselective
reaction with diethyl malonate and sodium ethoxide in etha-
nol, as described by Buckle et al.,6 to obtain compound
8 (yield 71%). Subsequent treatment of 8 with benzyl bro-
mide in DMF afforded the corresponding O-benzyl protected
9 in 55% yield. The structure of 9 was unequivocally assigned
using heteronuclear 2D-NMR (HSQC and HMBC) techniques.
The results of these studies confirmed the reported regio-
selectivity of the cycloaddition reaction used to obtain 8.6,7
The 4-methoxybenzyl moiety was selectively removed using
cerium ammonium nitrate (CAN) to afford triazole 10 in 35%
yield. The reactivity of 10 towards alkylating agents was then
investigated. Reaction of 10 with different alkyl and benzyl
halides in acetonitrile at room temperature afforded a mix-
ture of two isomers, which was separable by flashThis journal is © The Royal Society of Chemistry 2015chromatography. Two exemplifying compounds (structures 5
and 6) are presented in Scheme 1; other examples using dif-
ferent alkyl halides afforded comparable results.8 The struc-
tures of the three isomeric benzyl derivatives (4b, 5b and 6b)
were assigned by heteronuclear 2D-NMR (HSQC and HMBC).
The structure elucidation of these isomeric series will be
extensively discussed in a forthcoming full article. The data
indicated alkylation reactivity of 10 at both the N(b) and N(c)
ring positions, but not at N(a); this is in line with findings
reported for other ethyl triazole-4-carboxylates.8 In all cases,
compounds with structure 5 were obtained in higher yields
(47% and 45% for compounds 5a and 5b, respectively) com-
pared to compounds with structure 6 (30% for both 6a and
6b). Hydroxytriazoles 2 and 3 were obtained from the corre-
sponding O-benzylated derivatives 5 and 6 by catalytic hydro-
genation at atmospheric pressure pressure in 90% yield in
both cases.
To avoid the risk due to the explosive behavior of azides
with low C/N ratios, two different synthetic strategies
were designed for 1a and 1b. For 1a, diethyl diazomalonate
129 was treated with methylamine to yield the desired tria-
zole as the primary ammonium salt 13 (yield 79%). AfterMed. Chem. Commun., 2015, 6, 1285–1292 | 1287
Table 1 Measured pKa and C logP values for compounds 1a–3a, 1b–3b,
14–16
Compound Structure pKa
a C logPb
1a 6.21 ± 0.02 0.46
2a 5.14 ± 0.02 0.95
3a 5.54 ± 0.02 0.46
1b 6.22 ± 0.02 2.23
2b 5.14 ± 0.02 2.72
3b 5.38 ± 0.01 2.23
14 6.71 ± 0.01 1.19
15 4.21 ± 0.01 2.09
16 3.24 ± 0.05 1.61
a Determined by potentiometry (see ESI); each dataset represents
mean ± SD of five independent experiments. b Calculated by Bioloom
for windows v. 1.5, Biobite Corp., Claremont, CA, USA.
MedChemCommConcise Article
Pu
bl
ish
ed
 o
n 
28
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TÀ
 D
EG
LI
 ST
UD
I D
I T
OR
IN
O 
on
 11
/01
/20
16
 16
:16
:45
. 
View Article Onlineacidification and extraction with ethyl acetate, the free
hydroxytriazole 1a was isolated without any further purifica-
tion (quantitative yield). Conversely, for 1b, benzylazide was
treated with diethyl malonate and sodium ethoxide in etha-
nol, similar to the preparation of 8 (70% yield). Benzylation
of compounds 1a and 1b with benzylbromide in dimethyl-
formamide afforded the corresponding O-benzyl protected
compounds 4a and 4b (93% and 83% yield, respectively).Physicochemical profile and isosteric evaluation
In order to correctly modulate a functional group through a
bioisosteric approach, a wide range of isosteric replacements1288 | Med. Chem. Commun., 2015, 6, 1285–1292must be evaluated. The selection should be initially guided by
using some important physicochemical parameters such as pKa or
other.10 Usually being the first to be taken into account in han-
dling acidic isosteres of the carboxyl group, the pKa value of
selected hydroxytriazoles (compounds 1a–b, 2a–b and 3a–b) were
measured by potentiometric titration, in order to find a correlation
between the hydroxytriazole ring substitution and the pKa value
(Table 1). For comparison purposes, the pKa values of three other
hydroxylated pentatomic heterocyclic systems (hydroxypyrazole 14,
hydroxythiadiazole 15 and hydroxyfurazan 16) are also given.
Together with dissociation constants, lipophilicity is an
important physicochemical parameter that should be taken
into account in seeking bioisosterism. To evaluate this effect,
the calculated logP ĲC log P) values are included in Table 1.
In the hydroxytriazole system, the pKa value appears to be
influenced by substitution on the three endocyclic nitrogens
NĲa), NĲb) and NĲc). The NĲa)-substituted isomers 1a and 1b
present higher pKa values (6.21 and 6.22, respectively), simi-
lar to that of the hydroxypyrazole (14, pKa = 6.71). NĲb)- and
NĲc)-substituted compounds (2a–b, 3a–b) are slightly more
acidic, with pKa values in the 5.14–5.54 range. Although less
acidic compared to either hydroxythiadiazole 15 (pKa = 4.21)
or hydroxyfurazan 16 (pKa = 3.24), compounds 2a and 2b may
still be fully deprotonated at physiological pH. Comparison
of C logP values showed smaller values for the N-methyl
substituted hydroxytriazoles 1a, 2a and 3a compared to those
of compounds 14, 15 and 16. Hydroxytriazoles 1a–b, 2a–b
and 3a–b may thus be considered potential bioisosteres of a
carboxylic acid, since they exist predominantly in their
deprotonated states at physiological pH.Examples of successful bioisosteric application of the
hydroxytriazole moiety
The first application presented here is an example of a classi-
cal bioisosteric modulation, in which the carboxylic acid of a
lead compound is replaced with a series of isosteric moieties.
The biological activities of the resulting compounds are eval-
uated to determine the best bioisostere. The compound
selected for modulation is a natural compound, (S)-Glu, for
which specific agonists and antagonists are necessary in
order to characterize the physiological and pathological roles
of the different types of glutamate receptors (GluRs).11,12
In the second application, the potent OvCHT1 inhibitor
MDG-1-33A was modulated.5 The lack of any crystallographic
data makes this a challenging task, as such data would be
useful to guide the rational design of inhibitors. By modulat-
ing the triazole scaffold substitution, an advantageous posi-
tioning of the lipophilic substituent was achieved.
1) Targeting ionotropic AMPA GluRs using the hydroxy-
triazole moiety as a bioisosteric replacement. (S)-Glu (Table 2)
plays a major role in the transmission of excitatory signals in
the central nervous system, and is implicated in e.g. epilepsy,
pain, memory, excitotoxicity, and brain development.4 (S)-Glu
exerts its effects through two types of receptors: ligand-gated
ionotropic receptors (iGluRs) and G-protein-coupled metabotropicThis journal is © The Royal Society of Chemistry 2015
Med. Chem. Commun., 2015, 6, 1285–1292 | 1289This journal is © The Royal Society of Chemistry 2015
Table 2 Receptor binding affinities at native rat iGluRsa
IC50 (μM)
Compound Structure AMPA receptors KA receptors Ki (μM) NMDA receptors Distal carboxylate or its mimic pKa
(S)-Glu16 0.34 0.38 0.20 4.217
AMPA18 0.039 >100 >100 4.819
(+)-HFPA13 0.11 18 13 3.48
(S)-TDPA15 0.065 >100 >100b – not determined
17 (2-Me-TRPA) 3.1 [5.54 ± 0.09]c >100 >100 6.11 ± 0.02d
18 (3-Me-TRPA) 1.4 [5.87 ± 0.08]c >100 >100 6.42 ± 0.01d
a AMPA, KA, and NMDA receptors were studied using [3H]AMPA, [3H]KA, and [3H]CGP 39653 as radioligands, respectively. b [3H]CPP binding.
c Mean pIC50 ± SEM (shown in brackets) and the corresponding IC50 values were calculated from full concentration-response curves of three
individual experiments. d Determined by potentiometry (see ESI).
Scheme 2 Synthesis of AMPA GluRs agonists 17 and 18; (a) NaBH4, absolute ethanol, rt; (b) NBS, PPh3, dry CH2Cl2, 0 °C; (c) NaH, diethyl
acetamidomalonate, dry THF, rt; (d) H2/Pd, dry THF, rt; (e) 6 N HCl, reflux.
MedChemComm Concise Article
Pu
bl
ish
ed
 o
n 
28
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TÀ
 D
EG
LI
 ST
UD
I D
I T
OR
IN
O 
on
 11
/01
/20
16
 16
:16
:45
. 
View Article Online
MedChemCommConcise Article
Pu
bl
ish
ed
 o
n 
28
 M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TÀ
 D
EG
LI
 ST
UD
I D
I T
OR
IN
O 
on
 11
/01
/20
16
 16
:16
:45
. 
View Article Onlinereceptors (mGluRs).13 iGluRs are classified, depending on their
selective agonists, into NMDA ĲN-methyl-D-aspartate), AMPA Ĳ(RS)-
2-amino-3-Ĳ3-hydroxy-5-methylisoxazol-4-yl)propionic acid, Table
2) and KA (kainic acid) receptors. The second class, mGluRs, are
divided into three groups (I, II, III), each containing at least two
subtypes. The vast majority of both iGluR and mGluR subtypes
are considered to be interesting therapeutic targets for the treat-
ment of a number of neurologic and psychiatric diseases. Specific
agonists and antagonists are necessary to characterize the physio-
logical roles of the individual receptors.12 Since the late 1970s,
the bioisosteric approach has been the strategy of election to
design selective agonists and antagonists for AMPA/KA/NMDA
receptors. In this connection, a number of bioisosteric
replacements of the distal Glu carboxylic group have been
reported. Among them, the authors recently presented ĲR,S)-
2-amino-3-Ĳ4-hydroxy-1,2,5-oxadiazol-3-yl)propionic acid
(HFPA, Table 2) as Glu analogue obtained using the hydroxy-
1,2,5-oxadiazole scaffold.13
In an attempt to enhance selectivity for AMPA GluRs, the
hydroxytriazole scaffold was used to bioisosterically replace
the distal group of Glu. From a preliminary comparison
between the pKa values of the ethylcarboxylate 4-hydroxy-
triazole derivatives 2a and 3a and the Glu biosiosteres 17 and
18, we observed that replacement of the electron withdrawing
carboxyl substituent entails an increase of pKa (see Tables 1
and 2). In both isomeric methyl analogues, 2-Me-TRPA 17
and 3-MeTRPA 18, the pKa values of the hydroxytriazole moi-
ety were 6.11 and 6.42 respectively and an increase of 0.9 was
measured versus 2a and 3a respectively. When the hydroxy-
furazan series was studied, we observed an increase of pKa of
0.24, as depicted in Tables 1 and 2 (derivatives 16 and (+)-
HFPA). The extent of this effect depends on the hydroxyl
substituted heterocycle and, being the furazan a strongly
electron-acceptor group,14 a weaker effect on the acidic prop-
erties was observed. On the basis of these results, derivatives
17 and 18 more closely mimic the distal carboxylic acid of
Glu, maintaining the correct degree of deprotonation of the
hydroxyl group. Moreover, the hydroxytriazole scaffold also pro-
vides the opportunity of placing a small lipophilic portion ori-
ented in two different directions, being useful for increasing the
potency and/or selectivity towards a receptor subtype. It is
known that AMPA GluRs present lipophilic cavities close to the
distal carboxyl group in contrast to other Glu receptor subtypes.
The N-methyl groups in both 17 and 18 are directed in well-
defined areas within the Glu receptor binding site, unlike other
examples, such as TDPA15 or HFPA, where unsubstituted ring
systems have been used to mimic the distal carboxyl group.
The synthetic preparation of compounds 17 and 18 is
shown in Scheme 2.
Compounds 5a or 6a were first reduced to their corre-
sponding alcohols 19a–b (64% and 81% yield, respectively)
and subsequently reacted with N-bromosuccinimide (NBS) to
yield 20a (90% yield) and 20b (93% yield), respectively. Reac-
tion with diethyl ĳ(tert-butoxycarbonyl)amino]malonate in the
presence of NaH (70% yield in both cases) followed by cata-
lytic hydrogenation at atmospheric pressure furnished1290 | Med. Chem. Commun., 2015, 6, 1285–1292hydroxytriazoles 22a (95% yield) and 22b (85% yield). Final
deprotection of 22a and 22b in 6 N HCl at reflux gave hydro-
chloride salts of desired compounds 2-Me-TRPA (17) and
3-Me-TRPA (18) in quantitative yields.
The preliminary pharmacological results concerning iGluR
receptor subtypes are shown in Table 2. Both 17 and 18,
tested as racemic mixtures, present good selectivity within
their receptor subtypes. In particular, both compounds
presented a pharmacological profile quite similar to that of
AMPA, as neither compound showed any activity on KA or
NMDA receptors. The binding affinity of 18 toward the AMPA
receptor was expected, as the AMPA receptor is capable of
accommodating bulky groups in the area adjacent to the
aminoacidic function. At the same time, if compared with
AMPA, HFPA and TDPA, the low pKa value of the hydroxy-
ltriazoles should be behind the low activity showed by these
compounds. On the other hand, the N(b) substituted 2-Me-
TRPA (17) analogue presented a quite interesting activity pro-
file. In recent years, it was investigated the possibility to
replace the 3-hydroxyisoxazole in AMPA with other isosters
being able to extra substitute the ring and by effect to poses
lipophilic bulkiness in a topographic receptor space.
Recently, it was the case of 3-hydroxypyrazole AMPA ana-
logue20 (cpd6 in the reference) able to weakly but selectively
inhibit AMPA receptor with IC50 of 8.9 μM. This quite poor
result was explained by the author with the increased pKa value
of the 3-hydroxypyrazole compared to the 3-hydroxyisoxazole in
AMPA. 2-Me-TRPA (17) analogues, showing a lower pKa value of
hydroxypyrazole cpd6,20 was found able to selectively inhibit
AMPA receptor with IC50 of 3.1 μM, being almost three time
more active than cpd6.20 This preliminary quite interesting
results will open the possibility to design subtype selective
ligands by insertion of substituents on the NĲb) triazole position
that may reach non-conserved regions of the receptor.
2) Targeting OvCHT1 using the hydroxytriazole moiety
within a scaffold hopping approach. Onchocerciasis, also
known as river blindness, is a neglected tropical disease
caused by the parasitic worm Onchocerca volvulus (O. volvu-
lus), and is the world's second leading infectious cause of
blindness. An estimated 37 million people are infected with
river blindness, mostly in developing countries, in sub-
Saharan Africa and Central and South America.21 Addition-
ally, the possible emergence of Ivermectin-resistant O. volvulus
accelerates the need to develop new innovative therapeu-
tic strategies in this field, since the broad-spectrum
antiparasitic drug Ivermectin is the product currently most
widely used to treat the disease.22 OvCHT1 is a larval-stage-
specific chitinase that was recently identified as a potential
biological target affecting nematode development.23 As a
result of a blind screening program, Closantel was discovered
to be a potent and selective inhibitor of OvCHT1. Starting
from this lead, a series of Closantel analogues was prepared
to afford chitinase inhibitors with IC50 values in the low
nanomolar range.5 Of these, compound MDG-1-33A (Table 3)
was found to inhibit OvCHT1 with an IC50 value of 1.98 μM.
5
Using a scaffold hopping approach, the diiodophenolic core,This journal is © The Royal Society of Chemistry 2015
This journal is © The Royal Society of Chemistry 2015
Table 3 IC50 of OvCHT1 inhibition
Compound
Structure R =
IC50 (μM)a
MDG-1-33A 1.985
23 4.69 ± 0.29
24 5.11 ± 0.06
25 0.52 ± 0.03
26 0.41 ± 0.01
27 0.41 ± 0.04
a In vitro OvCHT1 inhibition activity was measured by fluorescence-
based assay (see ESI).23 Each dataset represents mean ± SD of three
independent assays.
Scheme 3 Synthesis of OvCHT1 chitinase inhibitors 23–27; (a) R–X, K2CO3
dry THF; (e) 4-phenoxyaniline, dry pyridine, dry THF, rt; (f) H2/Pd, dry THF, r
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View Article Onlinefound to be essential for chitinase inhibition, in MDG-1-33A
was replaced by the hydroxytriazole scaffold to give deriva-
tives 23–27. The synthetic routes for the preparation of com-
pounds 23–27 are outlined in Scheme 3. Alkylation of com-
pound 10 produced two isomers, which were separable by
flash chromatography. As previously discussed, compounds
with alkyl substituent on the N(b) atom were obtained in
higher amounts (range: 45–50% yield) than compounds with
alkyl substituent on the NĲc) atom (range 15–30% yield).
Basic hydrolysis yielded the carboxylic acid (around 90% yield
in all cases), which was subsequently converted into the cor-
responding acyl chloride. Reaction with 4-phenoxyaniline
yielded compounds 25–28 (40–65% range of yield). Catalytic
hydrogenation of 28 and 25 afforded hydroxytriazoles 23 and
24 respectively, in quantitative yields.
During the subsequent fine tuning modulation of the
hydroxytriazole scaffold (data not shown), the role of four pos-
sible substitutions on the triazole ring was determined consid-
ering all the NĲa), NĲb) and NĲc) positions. Because of the fact
that the phenolic group in MDG-1-33A analogues can be suc-
cessfully alkylated without affecting chitinase inhibition, the
O-alkylated triazole analogues were also considered. From
these studies, it was found that the presence of either NĲb) or
NĲc) alkyl substituents is beneficial to the potency that follow
the size of the alkyl substituent. The combination of these
facts together with the presence of a benzyl substituent on the
hydroxyl group afforded submicromolar range compounds.
IC50 values of MDG-1-33A triazole derivatives 23–27 are shown
in Table 3. The results of these scaffold hopping procedures
afforded three promising MDG-1-33A derivatives, compounds
25, 26 and 27, that inhibit OvCHT1 chitinase in the nM range.Conclusions
We have described the preparation of N-substituted hydroxy-
triazoles, as possible bioisosteres of the carboxyl functionality.Med. Chem. Commun., 2015, 6, 1285–1292 | 1291
, CH3CN, rt; (b) 2 N LiOH, THF, rt; (c) 2 N HCl, H2O; (d) (COCl)2, DMF,
t.
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View Article OnlineSynthetic strategies, spectral characterization of represen-
tative compounds, as well as the experimental acquisition
of the dissociation constants (pKa) of N-methyl- and
N-benzylhydroxytriazoles, are reported. Our results pro-
vided a new data set of possible carboxylic acid mimics
based on the hydroxytriazole scaffold with pKa values in
the 5.14–6.71 range and C log P values ranging from 0.46 to
2.72. This information might facilitate their application
within a bioisosteric approach to drug design. Two prelim-
inary bioisosteric applications of these new hydroxytrazole-
based isosteres of the carboxyl group are described: the
first is an example of classical bioisosteric modulation in
which the carboxylic acid of a lead compound is fine-
tuned; in the second example, this moiety was explored via
scaffold hopping replacement of the phenol ring present
in a lead compound bearing a salicylamide-type structure.
Detailed description of this research, together with other
bioisosteric applications currently under study, will be the
subject of forthcoming publications.
Acknowledgements
This research was supported by funding of the University of
Turin, Ricerca Locale 2013 and 2012 (to M. L. L. and D. B.).
Authors wish to thank Dr Annalisa Costale for performing all
the UPLC analysis and Dr Livio Stevanato for performing all
the NMR experiments and for maintenance of the instrument,
Dr Birgitte Nielsen for the binding studies on AMPA, KA, and
NMDA receptors.
References
1 N. Brown, Mol. Inf., 2014, 33, 458–462.
2 N. A. Meanwell, J. Med. Chem., 2011, 54, 2529–2591.
3 K. L. Kees, T. J. Caggiano, K. E. Steiner, J. J. Fitzgerald, M. J.Kates, T. E. Christos, J. M. Kulishoff, R. D. Moore and M. L.
McCaleb, J. Med. Chem., 1995, 38, 617–628.
4 G. Riedel, B. Platt and J. Micheau, Behav. Brain Res.,
2003, 140, 1–47.
5 M. Gooyit, N. Tricoche, S. Lustigman and K. D. Janda,
J. Med. Chem., 2014, 57, 5792–5799.
6 D. R. Buckle and C. J. M. Rockell, J. Chem. Soc., Perkin Trans.
1, 1982, 627–630.
7 M. Begtrup, Acta Chem. Scand., 1969, 23, 2025–2030.1292 | Med. Chem. Commun., 2015, 6, 1285–12928 D. R. Buckle, C. J. M. Rockell and R. S. Oliver, J. Heterocycl.
Chem., 1982, 19, 1147–1152.
9 N. D. Koduri, H. Scott, B. Hileman, J. D. Cox, M. Coffin, L.
Glicksberg and S. R. Hussaini, Org. Lett., 2012, 14, 440–443.
10 Bioisosterism in medicinal chemistry, ed. N. Brown, Wiley-
VCH Verlag GmbH & Co. KGaA, 2012, vol. 54.
11 J. N. C. Kew and J. A. Kemp, Psychopharmacology, 2005, 179,
4–29.
12 H. Bräuner-Osborne, J. Egebjerg, E. Nielsen, U. Madsen and
P. Krogsgaard-Larsen, J. Med. Chem., 2000, 43, 2609–2645.
13 M. L. Lolli, C. Giordano, D. S. Pickering, B. Rolando, K. B.
Hansen, A. Foti, A. Contreras-Sanz, A. Amir, R. Fruttero, A.
Gasco, B. Nielsen and T. N. Johansen, J. Med. Chem.,
2010, 53, 4110–4118.
14 R. Fruttero, D. Boschi, E. Fornatto, A. Serafino, A. Gasco and
O. Exner, J. Chem. Res., Synop., 1998, 495, 2545–2562.
15 T. N. Johansen, Y. L. Janin, B. Nielsen, K. Frydenvang, H.
Bräuner-Osborne, T. B. Stensbol, S. B. Vogensen, U. Madsen
and P. Krogsgaard-Larsen, Bioorg. Med. Chem., 2002, 10,
2259–2266.
16 R. P. Clausen, K. B. Hansen, P. Calí, B. Nielsen, J. R.
Greenwood, M. Begtrup, J. Egebjerg and H. Bräuner-
Osborne, Eur. J. Pharmacol., 2004, 499, 35–44.
17 K. Shimamoto and Y. Ohfune, J. Med. Chem., 1996, 39,
407–423.
18 S. B. Vogensen, K. Frydenvang, J. R. Greenwood, G.
Postorino, B. Nielsen, D. S. Pickering, B. Ebert, U. Bølcho, J.
Egebjerg, M. Gajhede, J. S. Kastrup, T. N. Johansen, R. P.
Clausen and P. Krogsgaard-Larsen, J. Med. Chem., 2007, 50,
2408–2414.
19 P. Wahl, U. Madsen, T. Banke, P. Krogsgaard-Larsen and A.
Schousboe, Eur. J. Pharmacol., 1996, 308, 211–218.
20 L. Jørgensen, B. Nielsen, D. S. Pickering, A. S. Kristensen, K.
Frydenvang, U. Madsen and R. P. Clausen, Neurochem. Res.,
2014, 39, 1895–1905.
21 J. E. Allen, O. Adjei, O. Bain, A. Hoerauf, W. H. Hoffmann,
B. L. Makepeace, H. Schulz-Key, V. N. Tanya, A. J. Trees, S.
Wanji and D. W. Taylor, PLoS Neglected Trop. Dis., 2008, 2.
22 S. Lustigman and J. P. McCarter, PLoS Neglected Trop. Dis.,
2007, 1.
23 C. Gloeckner, A. L. Garner, F. Mersha, Y. Oksov, N. Tricoche,
L. M. Eubanks, S. Lustigman, G. F. Kaufmann and K. D.
Janda, Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 3424–3429.This journal is © The Royal Society of Chemistry 2015
